Biogen begins laying off staff as it continues to push its new Alzheimer's drug
The layoffs at Biogen have begun.
In the wake of a controversial approval for its Alzheimer’s drug Aduhelm, Biogen started informing employees Wednesday that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
